- Stocks
- Healthcare
- NASDAQ: RIGL

Price (delayed)

$3.83

Market cap

$654.36M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.05

Enterprise value

$604.47M

Rigel Pharmaceuticals, Inc., is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with hematologic disorders, cancer and rare

The net income has surged by 69% year-on-year and by 33% since the previous quarter

Rigel Pharmaceuticals's EPS has surged by 64% YoY and by 29% QoQ

RIGL's equity is down by 13% from the previous quarter but it is up by 8% YoY

The quick ratio has contracted by 18% from the previous quarter and by 4.3% YoY

What are the main financial stats of RIGL

Market
Valuations
Earnings

Shares outstanding

170.85M

Market cap

$654.36M

Enterprise value

$604.47M

Price to earnings (P/E)

N/A

Price to book (P/B)

9.57

Price to sales (P/S)

4.52

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

4.19

Revenue

$144.12M

EBIT

-$3.83M

EBITDA

-$6.76M

Free cash flow

-$970,000

Per share
Balance sheet
Liquidity

EPS

-$0.05

Free cash flow per share

-$0.01

Book value per share

$0.4

Revenue per share

$0.85

TBVPS

$1.18

Total assets

$201.6M

Total liabilities

$133.49M

Debt

$34.94M

Equity

$68.11M

Working capital

$124.65M

Debt to equity

0.51

Current ratio

3.09

Quick ratio

2.87

Net debt/EBITDA

7.38

Margins
Efficiency
Dividend

EBITDA margin

-4.7%

Gross margin

99.4%

Net margin

-5.4%

Operating margin

-2.7%

Return on assets

-4.8%

Return on equity

-13.4%

Return on invested capital

-3.4%

Return on capital employed

-2.7%

Return on sales

-2.7%

Dividend yield

N/A

DPS

N/A

Payout ratio

N/A

How has the Rigel Pharmaceuticals stock price performed over time

Intraday

-0.26%

1 week

-4.25%

1 month

5.22%

1 year

53.2%

YTD

9.43%

QTD

-11.75%

How have Rigel Pharmaceuticals's revenue and profit performed over time

Revenue

$144.12M

Gross profit

$143.22M

Operating income

-$3.9M

Net income

-$7.73M

Gross margin

99.4%

Net margin

-5.4%

The operating margin has soared by 89% YoY and by 56% from the previous quarter

RIGL's operating income has surged by 85% year-on-year and by 53% since the previous quarter

RIGL's net margin has soared by 77% YoY and by 37% QoQ

The net income has surged by 69% year-on-year and by 33% since the previous quarter

What is Rigel Pharmaceuticals's growth rate over time

What is Rigel Pharmaceuticals stock price valuation

P/E

N/A

P/B

9.57

P/S

4.52

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

4.19

Rigel Pharmaceuticals's EPS has surged by 64% YoY and by 29% QoQ

The price to book (P/B) is 57% more than the 5-year quarterly average of 6.1 but 12% less than the last 4 quarters average of 10.9

RIGL's equity is down by 13% from the previous quarter but it is up by 8% YoY

The stock's price to sales (P/S) is 92% less than its 5-year quarterly average of 55.7 and 3.8% less than its last 4 quarters average of 4.7

Rigel Pharmaceuticals's revenue has increased by 33% YoY and by 8% QoQ

How efficient is Rigel Pharmaceuticals business performance

Rigel Pharmaceuticals's return on sales has surged by 88% YoY and by 55% QoQ

RIGL's return on invested capital has surged by 85% year-on-year and by 51% since the previous quarter

The return on assets has surged by 72% year-on-year and by 38% since the previous quarter

The ROE has soared by 65% year-on-year and by 34% since the previous quarter

What is RIGL's dividend

DPS

N/A

Dividend yield

N/A

Payout ratio

N/A

There are no recent dividends present for RIGL.

How did Rigel Pharmaceuticals financials performed over time

Rigel Pharmaceuticals's total assets is 51% more than its total liabilities

The total liabilities has soared by 78% YoY but it has contracted by 3.1% from the previous quarter

Rigel Pharmaceuticals's total assets has increased by 46% YoY but it has decreased by 7% from the previous quarter

RIGL's debt is 49% lower than its equity

RIGL's debt to equity is down by 25% YoY but it is up by 9% QoQ

RIGL's debt is down by 19% YoY and by 6% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.